Regorafenib dose escalation versus fixed dosing in refractory metastatic colorectal cancer: Survival outcomes from a sub-analysis of the ReTrITA study.

Signorelli, Carlo; Basso, Michele; Alessandra Calegari, Maria; Passardi, Alessandro; Gallio, Chiara; Lucchetti, Jessica; Valeria Zurlo, Ina; Dell'Aquila, Emanuela; Gemma, Donatello; Emiliani, Alessandra; Arrivi, Giulia; Zoratto, Federica; Grazia Morandi, Maria; Santamaria, Fiorenza; Dettori, Manuela; Cosimati, Antonella; Saltarelli, Rosa; Minelli, A.; Lucci-Cordisco, Emanuela; Giovanni Chilelli, Mario

doi:10.1200/jco.2026.44.2_suppl.136

Public

Regorafenib dose escalation versus fixed dosing in refractory metastatic colorectal cancer: Survival outcomes from a sub-analysis of the ReTrITA study.

Shared by NobleBlocks on Jan 10, 2026 • 12:00 AM UTC

Authors:

Carlo Signorelli

Michele Basso

Maria Alessandra Calegari

Abstract

136 Background: The ReTrITA study is a large, multicenter retrospective analysis evaluating real-world outcomes of regorafenib (R) and trifluridine/tipiracil (T) in refractory metastatic colorectal cancer (mCRC) across 17 Italian centers (2012–2023). This prespecified subgroup analysis focused on th...

Subject

Regorafenib

Medicine

Hazard ratio

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!